Send to

Choose Destination
See comment in PubMed Commons below
Adv Ther. 1999 Sep-Oct;16(5):210-8.

Primary immunosuppression with tacrolimus in renal transplantation: a multicenter, open-label study.

Author information

Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.


A multicenter, prospective, open-label trial was performed to assess the efficacy and safety of tacrolimus for primary immunosuppression in renal transplantation. Twenty patients were evaluated after receiving cadaveric and living, related or unrelated kidney transplants and were monitored for 6 months for patient and graft survival, incidence of acute rejection, and incidence of adverse events. Tacrolimus at a final mean dose of 0.11 mg/kg per day was 100% effective in preventing acute rejection in this Mexican population. Treatment was associated with a low incidence (10%) of posttransplant diabetes mellitus.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center